Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

Trial Details

NCT ID

NCT06297226

Phase

PHASE2

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Status

RECRUITING

Cancer Type

Relapsed/Refractory Multiple Myeloma

Interventions

• Arlocabtagene Autoleucel

Locations (sample)

• Birmingham, Alabama, United States|33.52066,-86.80249
• Gilbert, Arizona, United States|33.35283,-111.78903
• Little Rock, Arkansas, United States|34.74648,-92.28959
• Los Angeles, California, United States|34.05223,-118.24368
• San Francisco, California, United States|37.77493,-122.41942

Key Eligibility Criteria

• Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria.
• Received at least 4 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, …
• Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria.
• Participants must have measurable disease during screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.